<DOC>
	<DOCNO>NCT02254759</DOCNO>
	<brief_summary>This non-randomized , open-label , five treatment , fix sequence cross-over study investigate effect RO5186582 treatment CYP3A activity use midazolam probe CYP3A substrate , also assess pharmacodynamic measure brain electrical activity sedation explore pharmacodynamic interaction gama-amino butyric acid ( GABA ) A negative allosteric modulator RO5186582 prototypical GABAA positive allosteric modulator midazolam . The anticipated study duration nine week .</brief_summary>
	<brief_title>A Study RO5186582 Treatment Cytochrome P450 ( CYP ) 3A4 Activity Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy participant sign informed consent . A history epilepsy , convulsion significant head injury Significant history drug allergy , determine Investigator , know hypersensitivity ingredient study treatment Use drug substance , include herbal treatment St John 's Wort , know substrate , inducer inhibitor CYP3A4 within 30 day first dose administration Pregnant lactate Any clinically relevant abnormality , concomitant disease ongoing medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>